GO:0043325 phosphatidylinositol-3,4-bisphosphate binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043325 describes the molecular function of binding to phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2), a phosphoinositide phosphorylated at the 3' and 4' positions of the inositol ring.
• PI(3,4)P2 is a key signaling lipid that directly regulates effectors such as Akt, Lamellipodin, and pleckstrin, linking it to cell survival, chemotaxis, and cytokinesis.
• The synthesis and turnover of PI(3,4)P2 are spatially segregated in the endocytic pathway, with distinct enzymes producing and degrading it at different membrane compartments.
• PI(3,4)P2-specific phosphatases and binding proteins form a distinct branch of PI3K signaling, separate from the canonical PI(3,4,5)P3 pathway.
• Dysregulation of PI(3,4)P2 binding is implicated in cancer, immune disorders, and cataract formation, making it a potential therapeutic target.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of PI(3,4)P2 binding protein functions in health and disease.
Description
Phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) is a membrane phospholipid that serves as a critical second messenger in eukaryotic cells. The molecular function of binding to this lipid, formally annotated as GO:0043325, is mediated by specialized protein domains such as pleckstrin homology (PH) domains that recognize the phosphorylated inositol headgroup. This binding event recruits effector proteins to specific membrane compartments, thereby propagating intracellular signals that control diverse processes including cell survival, migration, and division. Understanding GO:0043325 is therefore essential for researchers studying phosphoinositide signaling, membrane trafficking, and related diseases. The importance of PI(3,4)P2 binding is underscored by its direct role in activating the proto-oncogene Akt, a central node in growth factor signaling. Moreover, PI(3,4)P2-specific phosphatases and binding proteins constitute a distinct branch of PI3K signaling, highlighting the need to study this function independently of the more widely known PI(3,4,5)P3 pathway. Recent work has also revealed that PI(3,4)P2 synthesis and turnover are spatially segregated in the endocytic pathway, adding another layer of complexity to how binding proteins are regulated. This article provides a comprehensive overview of GO:0043325, covering its definition, biological significance, key genes, disease associations, and modern research methods including CRISPR-based models.
phosphatidylinositol-3,4-bisphosphate binding At A Glance
| GO ID | GO:0043325 |
|---|---|
| GO term | phosphatidylinositol-3,4-bisphosphate binding |
| Ontology | molecular_function |
| Synonym | (none) |
| Major function | Binding to phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2), a phosphoinositide second messenger |
| Definition source | QuickGO |
| Common binding domains | Pleckstrin homology (PH) domains, e.g., in pleckstrin, Akt, Lamellipodin |
| Subcellular context | Membranes of endocytic pathway, plasma membrane, and nuclear compartments |
| Related lipids | PI(3,4,5)P3, PI(4,5)P2, PI(3)P |
What Is GO:0043325?
GO:0043325, phosphatidylinositol-3,4-bisphosphate binding, is defined as the binding to phosphatidylinositol-3,4-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' and 4' positions. In other words, it is the molecular function of a protein or domain physically interacting with PI(3,4)P2, typically through electrostatic and stereospecific recognition of the lipid headgroup.
Why Is phosphatidylinositol-3,4-bisphosphate binding Important in Cell Biology?
GO:0043325 is important because PI(3,4)P2 binding directly controls the recruitment and activation of key signaling proteins that regulate cell survival, proliferation, migration, and cytokinesis. Dysregulation of this binding function contributes to cancer progression, immune cell chemotaxis defects, and developmental abnormalities such as cataract formation. Thus, studying this molecular function provides mechanistic insights into both normal physiology and disease pathogenesis.
• PI(3,4)P2 binding directly activates Akt, a major oncogenic kinase, linking this function to cancer cell survival and growth.
• Lamellipodin binding to PI(3,4)P2 regulates chemotaxis of malignant B lymphocytes, implicating this function in immune cell migration and lymphoma dissemination.
• PI(3,4)P2-mediated cytokinetic abscission is essential to prevent early senescence and cataract formation, highlighting its role in tissue homeostasis.
• The spatial segregation of PI(3,4)P2 synthesis and turnover in the endocytic pathway suggests that binding proteins are recruited to specific membrane domains with high precision.
• PI(3,4)P2-specific phosphatases and effector proteins form a distinct branch of PI3K signaling, offering alternative therapeutic targets.
• Parotid secretory protein binds PI(3,4)P2, indicating a role for this lipid in exocrine gland function.
• The C-terminal PH domain of human pleckstrin binds PI(3,4)P2 with high specificity, providing a structural paradigm for understanding this interaction.
• Nuclear PI(3,4,5)P3 interactome studies have uncovered enrichment in nucleolar proteins, suggesting that phosphoinositide binding may also occur in nuclear compartments.
• CRISPR screens can identify novel PI(3,4)P2 binding proteins and their functional relevance in disease models.
• Understanding GO:0043325 can guide the development of drugs targeting PI(3,4)P2-protein interactions for cancer and immune disorders.
Molecular Mechanism of phosphatidylinositol-3,4-bisphosphate binding
Recognition of the PI(3,4)P2 headgroup
In simple terms: Proteins bind to PI(3,4)P2 by recognizing its specific phosphate groups at positions 3 and 4.
The binding of proteins to PI(3,4)P2 typically involves specialized lipid-binding domains such as pleckstrin homology (PH) domains, which form a pocket that accommodates the inositol headgroup. Structural studies of the C-terminal PH domain of human pleckstrin revealed the molecular basis for PI(3,4)P2 binding, showing specific interactions with the 3- and 4-phosphate groups. This stereospecific recognition ensures that only PI(3,4)P2, and not other phosphoinositides, is bound with high affinity.
Membrane recruitment and spatial segregation
In simple terms: Binding brings proteins to specific membrane locations where PI(3,4)P2 is produced.
PI(3,4)P2 is generated at distinct membrane compartments, and its synthesis and turnover are spatially segregated in the endocytic pathway. This spatial segregation ensures that binding proteins are recruited to precise subcellular locations, such as endosomal membranes or the plasma membrane, where they can interact with downstream effectors. For example, Lamellipodin binds PI(3,4)P2 at the leading edge of migrating cells to regulate chemotaxis.
Activation of downstream signaling
In simple terms: Once bound, PI(3,4)P2 can switch on signaling proteins like Akt.
Binding of PI(3,4)P2 to Akt directly regulates its kinase activity, independent of PI(3,4,5)P3. This interaction is critical for Akt-mediated survival and proliferation signals. Similarly, PI(3,4)P2 binding to Lamellipodin promotes actin cytoskeleton remodeling during cell migration. These examples illustrate how the binding event translates into diverse cellular outcomes.
Regulation by phosphatases and turnover
In simple terms: Enzymes that degrade PI(3,4)P2 can shut down the binding signal.
PI(3,4)P2-specific phosphatases, such as INPP4B, hydrolyze PI(3,4)P2 and thereby terminate binding-dependent signaling. The balance between synthesis by PI3K and degradation by phosphatases determines the steady-state levels of PI(3,4)P2 and the duration of effector recruitment. This regulatory layer is a distinct branch of PI3K signaling and is often dysregulated in cancer.
Nuclear and non-canonical roles
In simple terms: PI(3,4)P2 binding may also occur in the nucleus, not just at the cell membrane.
Recent proteomic studies of the nuclear PI(3,4,5)P3 interactome uncovered an enrichment in nucleolar proteins, suggesting that phosphoinositide binding, including potentially PI(3,4)P2, may have nuclear functions. Although direct evidence for nuclear PI(3,4)P2 binding is still emerging, these findings expand the potential scope of GO:0043325 beyond the cytoplasm.
Key Genes Involved in GO:0043325 phosphatidylinositol-3,4-bisphosphate binding
The following genes encode proteins that bind phosphatidylinositol-3,4-bisphosphate or regulate its metabolism, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AKT1 | Serine/threonine kinase activated by PI(3,4)P2 binding | Direct regulation by PI(3,4)P2; cancer drug target |
| PLEK | Pleckstrin, contains PH domain that binds PI(3,4)P2 | Structural model for PI(3,4)P2 recognition |
| RAPH1 | Lamellipodin, binds PI(3,4)P2 to regulate chemotaxis | Role in malignant B lymphocyte migration |
| INPP4B | Phosphatase that hydrolyzes PI(3,4)P2 | Tumor suppressor, regulates PI(3,4)P2 levels |
| PSP | Parotid secretory protein, binds PI(3,4)P2 | Exocrine gland function |
| PIK3CA | Catalytic subunit of PI3K, synthesizes PI(3,4)P2 | Oncogene, upstream of PI(3,4)P2 production |
| PIK3CB | PI3K beta isoform, contributes to PI(3,4)P2 synthesis | Signaling in endocytic pathway |
| PIK3CD | PI3K delta isoform, produces PI(3,4)P2 in immune cells | Immune cell signaling |
| PIK3R1 | Regulatory subunit of PI3K | Modulates PI3K activity and PI(3,4)P2 levels |
| PTEN | Lipid phosphatase that indirectly affects PI(3,4)P2 | Tumor suppressor, PI3K pathway |
| SHIP1 | Inositol polyphosphate 5-phosphatase, produces PI(3,4)P2 from PI(3,4,5)P3 | Immune cell regulation |
| SHIP2 | Inositol polyphosphate 5-phosphatase, produces PI(3,4)P2 | Metabolic signaling |
| OCRL | Inositol polyphosphate 5-phosphatase, may affect PI(3,4)P2 | Lowe syndrome, endocytic trafficking |
| SYNJ1 | Synaptojanin 1, phosphoinositide phosphatase | Endocytosis, PI(3,4)P2 turnover |
| AP2M1 | Clathrin adaptor, binds phosphoinositides | Endocytic pathway, potential PI(3,4)P2 effector |
| DNM2 | Dynamin 2, GTPase involved in endocytosis | Membrane remodeling, PI(3,4)P2-rich membranes |
| ACAP1 | ArfGAP with coiled-coil, binds phosphoinositides | Endocytic recycling |
| CIT | Citron kinase, involved in cytokinesis | PI(3,4)P2-mediated abscission |
How Is phosphatidylinositol-3,4-bisphosphate binding Regulated?
The binding of PI(3,4)P2 to effector proteins is regulated by the balance between its synthesis and degradation. PI3K enzymes, particularly class I PI3Ks, generate PI(3,4)P2 directly or indirectly through dephosphorylation of PI(3,4,5)P3 by SHIP1/2 phosphatases. Conversely, INPP4B and other phosphatases hydrolyze PI(3,4)P2, terminating binding-dependent signals. Spatial segregation of these enzymes within the endocytic pathway ensures that PI(3,4)P2 binding occurs at specific membrane domains. Additionally, the availability of binding proteins themselves can be regulated by phosphorylation or other post-translational modifications, although specific examples are still being elucidated.
phosphatidylinositol-3,4-bisphosphate binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AKT1 | Cancer (e.g., breast, colorectal) | Knockout or point mutation in cancer cell lines |
| INPP4B | Cancer (tumor suppressor loss) | Knockout in breast cancer cells |
| RAPH1 | Lymphoma metastasis | Knockout in B lymphoma cell lines |
| CIT | Cataract, senescence | Knockout in lens epithelial cells |
| PLEK | Platelet dysfunction | Point mutation in PH domain |
Cancer
PI(3,4)P2 binding is directly linked to cancer through Akt activation, which promotes cell survival and proliferation. Lamellipodin binding to PI(3,4)P2 regulates chemotaxis of malignant B lymphocytes, potentially contributing to lymphoma dissemination. Loss of INPP4B, a PI(3,4)P2 phosphatase, leads to elevated PI(3,4)P2 levels and is associated with poor prognosis in several cancers.
Cataract and senescence
PI(3,4)P2-mediated cytokinetic abscission is essential to prevent early senescence and cataract formation. Disruption of this process in lens epithelial cells leads to cataract development.
Immune disorders
PI(3,4)P2 binding regulates immune cell migration and function. For example, Lamellipodin-dependent chemotaxis of malignant B lymphocytes requires PI(3,4)P2 binding, and dysregulation may contribute to immune cell trafficking abnormalities.
From phosphatidylinositol-3,4-bisphosphate binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PI(3,4)P2 binding affect Akt activation? | AKT1 PH domain point mutation (knock-in) |
| How does INPP4B loss alter PI(3,4)P2 levels? | INPP4B knockout cell line |
| What is the role of Lamellipodin in chemotaxis? | RAPH1 knockout in B lymphocytes |
| Does PI(3,4)P2 binding regulate cytokinesis? | CIT knockout or tagged knock-in in HeLa cells |
| Can overexpression of PI(3,4)P2 binding domain alter signaling? | Overexpression of PH domain-GFP fusion |
| Identify novel PI(3,4)P2 binding proteins | CRISPR library screening with lipid binding assay |
How to Study the phosphatidylinositol-3,4-bisphosphate binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipid overlay assay | Direct binding of proteins to PI(3,4)P2 | Screening candidate proteins |
| Isothermal titration calorimetry | Binding affinity (Kd) for PI(3,4)P2 | Quantifying domain-lipid interactions |
| Fluorescence microscopy | Subcellular localization of PI(3,4)P2 and binding proteins | Live-cell imaging |
| Co-immunoprecipitation | Protein-protein interactions in PI(3,4)P2-dependent complexes | Identifying signaling partners |
| CRISPR knockout screens | Genes required for PI(3,4)P2-mediated phenotypes | Functional genomics |
| Proteomics (affinity purification) | PI(3,4)P2 interactome | Discovering novel binding proteins |
| RNA-seq | Transcriptional changes upon PI(3,4)P2 pathway modulation | Pathway analysis |
Lipid overlay and binding assays
Lipid overlay assays using nitrocellulose membranes spotted with various phosphoinositides can identify PI(3,4)P2 binding proteins. This method is useful for screening candidate proteins and determining lipid specificity.
Structural biology (X-ray crystallography, NMR)
Structural studies of protein domains in complex with PI(3,4)P2 headgroup analogs reveal the molecular basis of binding specificity, as demonstrated for the pleckstrin PH domain.
Live-cell imaging with fluorescent probes
Genetically encoded PI(3,4)P2 biosensors (e.g., PH domain-GFP fusions) allow real-time visualization of lipid distribution and binding dynamics in living cells.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens coupled with PI(3,4)P2 binding readouts can identify novel regulators and effectors of this lipid.
How CRISPR Can Be Used to Study GO:0043325 phosphatidylinositol-3,4-bisphosphate binding
Knockout
CRISPR knockout of genes encoding PI(3,4)P2 binding proteins (e.g., AKT1, RAPH1) or metabolic enzymes (e.g., INPP4B) allows researchers to assess loss-of-function phenotypes in cell migration, survival, and cytokinesis. Knockout cell lines can be used to validate binding specificity and downstream signaling.
Point Mutation
Introducing point mutations in the lipid-binding domain (e.g., PH domain of AKT1 or pleckstrin) via CRISPR knock-in can abolish PI(3,4)P2 binding without affecting protein expression, enabling precise structure-function studies.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) of PI(3,4)P2 binding proteins allows for localization and interaction studies in endogenous contexts. This approach preserves native regulation and can be combined with live-cell imaging.
Overexpression
Overexpression of wild-type or mutant PI(3,4)P2 binding domains can act as dominant-negative or constitutively active tools to manipulate signaling pathways. For example, overexpression of a PI(3,4)P2-specific PH domain can sequester the lipid and inhibit downstream effects.
How EDITGENE Supports phosphatidylinositol-3,4-bisphosphate binding Research
Researchers studying phosphatidylinositol-3,4-bisphosphate binding-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of PI(3,4)P2 binding proteins and their regulators.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylinositol-3,4-bisphosphate binding research.
Frequently Asked Questions About phosphatidylinositol-3,4-bisphosphate binding
What is phosphatidylinositol-3,4-bisphosphate binding?
It is the molecular function defined by GO:0043325, where a protein binds to the lipid phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2), typically via specialized domains such as PH domains.
What genes are involved in phosphatidylinositol-3,4-bisphosphate binding?
Key genes include AKT1, PLEK, RAPH1 (Lamellipodin), INPP4B, and PSP, among others.
How does PI(3,4)P2 binding regulate cell signaling?
Binding recruits effector proteins to membranes, activating pathways such as Akt-mediated survival and Lamellipodin-mediated chemotaxis.
What diseases are associated with PI(3,4)P2 binding?
Cancer, immune disorders, and cataract formation have been linked to dysregulated PI(3,4)P2 binding.
What is the role of INPP4B in PI(3,4)P2 signaling?
INPP4B is a phosphatase that hydrolyzes PI(3,4)P2, thereby terminating binding-dependent signals and acting as a tumor suppressor.
How can CRISPR be used to study PI(3,4)P2 binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes encoding PI(3,4)P2 binding proteins or metabolic enzymes.
What methods are used to detect PI(3,4)P2 binding?
Lipid overlay assays, isothermal titration calorimetry, fluorescence microscopy, and proteomics are commonly used.
Is PI(3,4)P2 binding specific to certain cell types?
PI(3,4)P2 binding occurs in many cell types, but its functional consequences can be cell-type specific, such as in malignant B lymphocytes or lens epithelial cells.
What is the difference between PI(3,4)P2 and PI(3,4,5)P3 binding?
PI(3,4)P2 is phosphorylated at positions 3 and 4, while PI(3,4,5)P3 has an additional phosphate at position 5; they bind overlapping but distinct sets of effector proteins.
How does spatial segregation affect PI(3,4)P2 binding?
Synthesis and turnover of PI(3,4)P2 are spatially segregated in the endocytic pathway, ensuring that binding proteins are recruited to specific membrane domains.
Conclusion
GO:0043325, phosphatidylinositol-3,4-bisphosphate binding, represents a crucial molecular function that links lipid signaling to diverse cellular outcomes, including survival, migration, and cytokinesis. Its dysregulation is implicated in cancer, immune disorders, and cataract formation, making it a compelling target for basic and translational research. Advances in CRISPR-based genome editing and lipid detection methods now enable precise interrogation of PI(3,4)P2 binding proteins in physiologically relevant models. EDITGENE provides end-to-end services to support these efforts, from custom knockout and knock-in cell lines to high-throughput screens and bioinformatics analysis.
References
- 1. Wang H et al.. 2020. Phosphatidylinositol 3,4-bisphosphate synthesis and turnover are spatially segregated in the endocytic pathway.. J Biol Chem 295(4):1091-1104 PMID: 31831620
- 2. Li H et al.. 2015. Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling.. Cell Signal 27(9):1789-98 PMID: 26022180
- 3. Li H et al.. 2016. Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes.. J Immunol 196(2):586-95 PMID: 26695371
- 4. Venkatesh SG et al.. 2011. Parotid secretory protein binds phosphatidylinositol (3,4) bisphosphate.. J Dent Res 90(9):1085-90 PMID: 21628641
- 5. Edlich C et al.. 2005. Structure and phosphatidylinositol-(3,4)-bisphosphate binding of the C-terminal PH domain of human pleckstrin.. Structure 13(2):277-86 PMID: 15698571
- 6. Gulluni F et al.. 2021. PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation.. Science 374(6573):eabk0410 PMID: 34882480
- 7. Mazloumi Gavgani F et al.. 2021. Nuclear Phosphatidylinositol 3,4,5-Trisphosphate Interactome Uncovers an Enrichment in Nucleolar Proteins.. Mol Cell Proteomics 20:100102 PMID: 34048982
- 8. Franke TF et al.. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.. Science 275(5300):665-8 PMID: 9005852
